CNMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CNMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Conmed's revenue per share for the three months ended in Mar. 2024 was $9.99. Conmed's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $39.97.
During the past 12 months, the average Revenue Per Share Growth Rate of Conmed was 11.50% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 10.50% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 5.00% per year. During the past 10 years, the average Revenue Per Share Growth Rate was 3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Conmed's Revenue per Share or its related term are showing as below:
During the past 13 years, Conmed's highest 3-Year average Revenue Per Share Growth Rate was 40.80% per year. The lowest was -1.20% per year. And the median was 5.90% per year.
The historical data trend for Conmed's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Conmed Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Revenue per Share | Get a 7-Day Free Trial | 32.38 | 29.27 | 31.37 | 34.80 | 39.46 |
Conmed Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Revenue per Share | Get a 7-Day Free Trial | 9.47 | 9.99 | 9.61 | 10.38 | 9.99 |
For the Medical Devices subindustry, Conmed's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Conmed's PS Ratio distribution charts can be found below:
* The bar in red indicates where Conmed's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Conmed's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue Per Share (A: Dec. 2023 ) | = | Revenue (A: Dec. 2023 ) | / | Shares Outstanding (Diluted Average) (A: Dec. 2023 ) |
= | 1244.744 | / | 31.548 | |
= | 39.46 |
Conmed's Revenue Per Share for the quarter that ended in Mar. 2024 is calculated as
Revenue Per Share (Q: Mar. 2024 ) | = | Revenue (Q: Mar. 2024 ) | / | Shares Outstanding (Diluted Average) (Q: Mar. 2024 ) |
= | 312.273 | / | 31.272 | |
= | 9.99 |
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $39.97
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Conmed (NYSE:CNMD) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Conmed's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Peters Stanley W Iii | officer: VP GM General Surgery | C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
Todd W. Garner | officer: Executive Vice President & CFO | C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
Edward A. Clifford | officer: VP Global Manufacturing | C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
Curt R Hartman | director | C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
John D. Ferrell | officer: Executive Vice President - HR | C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
Brian Concannon | director | HAEMONETICS CORP, 400 WOOD RD, BRAINTREE MA 02184-9144 |
Peter K Shagory | officer: EVP,STRAT & CORP DEVT | C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
Daniel Jonas | officer: Vice President/Legal Affairs, other: General Counsel | C/O CONMED CORP, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
Terence M Berge | officer: VP Corp. Treasurer | C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
Johonna Marie Pelletier | officer: Treasurer and VP, Tax | C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
Jerome J. Lande | director | 1 WORLD TRADE CENTER, 85TH FLOOR, NEW YORK NY 10007 |
Brent Lalomia | officer: Vice President QA and RA | C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
John Jed Kennedy | officer: VP GM GI | C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
Mark E Tryniski | director | C/O CONMED CORP., 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
Pat Beyer | officer: President-Conmed International | C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773 |
From GuruFocus
By Business Wire Business Wire • 11-15-2022
By Business Wire Business Wire • 06-02-2022
By Business Wire • 08-24-2023
By GuruFocus Research • 09-16-2023
By Business Wire Business Wire • 08-11-2022
By GuruFocus Research • 10-30-2023
By Business Wire • 07-26-2023
By Business Wire Business Wire • 03-22-2023
By Business Wire Business Wire • 12-05-2022
By Business Wire Business Wire • 08-09-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.